Shanghai-Israel Fund Co-Leads $9 Million Funding Of Rapid Medical
Published: Jul 19, 2017
July 19, 2017 -- The Shanghai-Israel Investment Fund and BRM Group, an Israeli investment firm, co-led a $9 million Series B financing in Israel's Rapid Medical. Rapid is developing two neurovascular interventional devices: the Tigertriever Revascularization device used to remove stoke-causing clots, and the Comaneci Adjustable Remodeling Mesh, an external device used during embolization procedures. The B round will allow Rapid Medical to begin a US clinical trial of Tigertriever and European commercialization of both the Tigertriever and Comaneci devices.